Baker BROS. Advisors LP raised its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 10.0% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,045,336 shares of the company's stock after purchasing an additional 1,000,000 shares during the period. Replimune Group accounts for approximately 1.3% of Baker BROS. Advisors LP's holdings, making the stock its 12th biggest position. Baker BROS. Advisors LP owned approximately 16.14% of Replimune Group worth $121,057,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of REPL. Nisa Investment Advisors LLC lifted its stake in shares of Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company's stock worth $45,000 after acquiring an additional 4,946 shares during the period. Point72 DIFC Ltd bought a new position in shares of Replimune Group in the second quarter valued at approximately $57,000. Erste Asset Management GmbH bought a new position in shares of Replimune Group in the third quarter valued at approximately $133,000. Arizona State Retirement System bought a new position in shares of Replimune Group in the second quarter valued at approximately $108,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Replimune Group by 82.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company's stock valued at $144,000 after acquiring an additional 5,926 shares in the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.
Replimune Group Price Performance
REPL stock traded down $0.53 on Monday, hitting $13.55. 837,218 shares of the company's stock traded hands, compared to its average volume of 1,063,923. The stock has a fifty day moving average of $11.89 and a 200-day moving average of $10.02. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $17.00. The stock has a market cap of $927.09 million, a price-to-earnings ratio of -4.62 and a beta of 1.19. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18.
Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.07. On average, analysts forecast that Replimune Group, Inc. will post -2.99 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
REPL has been the subject of several recent analyst reports. BMO Capital Markets increased their price objective on shares of Replimune Group from $14.00 to $18.00 and gave the company an "outperform" rating in a report on Friday, November 22nd. JPMorgan Chase & Co. increased their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, September 24th. Roth Mkm initiated coverage on shares of Replimune Group in a report on Tuesday, August 27th. They issued a "buy" rating and a $17.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $17.00 price objective on shares of Replimune Group in a report on Friday, November 22nd. Finally, Roth Capital raised shares of Replimune Group to a "strong-buy" rating in a research note on Tuesday, August 27th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $17.00.
Read Our Latest Report on Replimune Group
Insider Activity at Replimune Group
In related news, insider Konstantinos Xynos sold 7,246 shares of the firm's stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 8.80% of the stock is currently owned by company insiders.
About Replimune Group
(
Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
Featured Articles
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
